#United States #Class Action #Philadelphia #Berger Montague #MoonLake

Important Legal Notice for MoonLake Immunotherapeutics Investors

In a recent announcement, the national law firm Berger Montague PC has launched a class action lawsuit against MoonLake Immunotherapeutics, traded under NASDAQ symbol MLTX. This comes after serious concerns were raised regarding the company's sole drug candidate, sonelokimab (SLK), which is currently under clinical evaluation for treating specific skin conditions.

Background of the Lawsuit

The lawsuit targets investors who acquired shares of MoonLake during the period from March 10, 2024, to September 29, 2025. According to court documents, the allegations indicate that MoonLake, along with its executives, disseminated misleading statements about SLK's potential clinical benefits, wrongly portraying it as superior to existing treatments such as the FDA-approved BIMZELX.

Following the release of Phase 3 clinical trial results on September 28, 2025, the situation escalated dramatically. The results reportedly fell short of expectations, showing that SLK did not perform as well as competitors. This disappointing outcome led analysts to describe the data as disastrous, causing MoonLake's stock to plummet by nearly 90%, equating to a loss of $55.75 per share in just one trading day.

Call to Action

Investors who purchased MoonLake securities in the specified class period have until December 15, 2025, to act. They can seek to be appointed as lead plaintiff representatives for the lawsuit. This is an essential step for those wishing to protect their rights and potentially recover losses.

If you believe you qualify for this class action, further information is available through Berger Montague's contact methods: Andrew Abramowitz can be reached at [email protected] or via phone at (215) 875-3015, and Caitlin Adorni at [email protected] or (267) 764-4865.

About Berger Montague

Berger Montague has established itself as a leading law firm in the area of complex civil litigation, known for handling class actions and mass torts across various legal domains in both federal and state courts. With a notable track record of over $2.4 billion in post-trial judgments within 2025 alone, the firm has championed numerous precedent-setting cases, recovering significant amounts on behalf of its clients.

For over 55 years, Berger Montague has devoted itself to advocating for individuals and classes facing challenges against corporate wrongdoing in areas including antitrust, consumer protection, and securities law.

Final Note

As the deadline for investors to act draws closer, those affiliated with MoonLake Immunotherapeutics must remain vigilant and informed. Whether through the class action or other avenues, the ultimate goal is to ensure that investor rights are upheld and justice is served.

Stay in the loop with current developments regarding this lawsuit as more information becomes available in the coming weeks.